New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors (Q34866630)

5 August 2017

1 reference

title

New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors (English)

1 reference

5 August 2017

0 references

1 reference

1

Ian Chopra

1 reference

5 August 2017

language of work or name

1 reference

1 July 2002

1 reference

5 August 2017

published in

Drug Resistance Updates

1 reference

5 August 2017

volume

5

1 reference

5 August 2017

issue

3-4

1 reference

5 August 2017

page(s)

119-125

1 reference

"Glycylcyclines". 3. 9-Aminodoxycyclinecarboxamides.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Research and development of antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Glycylcyclines: third-generation tetracycline antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro activities of two glycylcyclines against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In-vitro activity of two glycylcyclines against enterococci resistant to other agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pump

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Activity of glycylcyclines CL 329998 and CL 331002 against minocycline-resistant and other strains of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

High mutation frequencies among Escherichia coli and Salmonella pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

The challenge of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Multiple antibiotic resistance and efflux

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Mutator clones of Neisseria meningitidis in epidemic serogroup A disease

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Detection of tetracyclines and efflux pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Origin of tetracycline efflux proteins: conclusions from nucleotide sequence analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro activities of two new glycylcyclines, N,N-dimethylglycylamido derivatives of minocycline and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

In vitro activities of two glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900051-1

7 January 2021

10.1016/S1368-7646(02)00051-1

Identifiers

DOI

1 reference

5 August 2017

1 reference